Fig. 5.
Fig. 5. Reduced SIRP expression on leukemic blasts. Mononuclear BM or PB cells from AML and CML patients were immunolabeled with CD45-FITC and MoAb P3C4 (IgG2a), followed by PE-conjugated goat anti-mouse IgG2a-specific antiserum (filled histogram). Nonbinding IgG2a antibody was used as negative control (black line). The histograms show representative examples of SIRP expression gated on CD45low leukemic blasts. AML samples were divided into 3 groups: no expression (▵median of 0 to 5), reduced expression (▵median of 10 to 150), and normal expression of SIRP (▵median over 150). The number of analyzed samples is given in brackets.

Reduced SIRP expression on leukemic blasts. Mononuclear BM or PB cells from AML and CML patients were immunolabeled with CD45-FITC and MoAb P3C4 (IgG2a), followed by PE-conjugated goat anti-mouse IgG2a-specific antiserum (filled histogram). Nonbinding IgG2a antibody was used as negative control (black line). The histograms show representative examples of SIRP expression gated on CD45low leukemic blasts. AML samples were divided into 3 groups: no expression (▵median of 0 to 5), reduced expression (▵median of 10 to 150), and normal expression of SIRP (▵median over 150). The number of analyzed samples is given in brackets.

Close Modal

or Create an Account

Close Modal
Close Modal